The clinical development of new mitotic inhibitors that stabilize the microtubule

Anti-Cancer Drugs

Volumn 15, Issue 6, 2004, Pages 553-558

  Mani, Sridhar ^a,d   Macapinlac Jr , Manuel ^a   Goel, Sanjay ^a   Verdier Pinard, Dominik ^a   Fojo, Tito ^b   Rothenberg, Mace ^c   Colevas, Dimitrios ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d Jack D Weiler Hospital   (United States)

Author keywords

Discodermolide; Eluethrobin; Epothilones; Microtubule binding drugs; Taxanes

Indexed keywords

AMINOTRANSFERASE; ANTIMITOTIC AGENT; BMS 184476; BMS 188791; BMS 310705; CEMADOTIN; CREMOPHOR; DISCODERMOLIDE; EPOTHILON C; EPOTHILONE A; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; IXABEPILONE; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; PACLITAXEL DERIVATIVE; T 138067; T 900607; TAXANE DERIVATIVE; TXD 258; UNCLASSIFIED DRUG; XAA 296;

ANEMIA; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CELL CULTURE; CANCER MODEL; CYTOPATHOGENIC EFFECT; DIARRHEA; DOSE RESPONSE; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG METABOLISM; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; IC 50; MAXIMUM TOLERATED DOSE; MITOSIS INHIBITION; NAUSEA; NEUROTOXICITY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW;

ALKANES; ANIMALS; CARBAMATES; CELL LINE, TUMOR; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; EPOTHILONES; HUMANS; LACTONES; MICROTUBULE-ASSOCIATED PROTEINS; MICROTUBULES; MITOSIS; MOLECULAR STRUCTURE; MULTICENTER STUDIES; PYRONES;

EID: 3142704182     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000131681.21637.b2     Document Type: Review

References (39)

1. Kavallaris M, Verrills NM, Hill BT. Anticancer therapy with novel tubulin-interacting drugs. Drug Resist Update 2001; 4:392-401.
2. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to Taxol. Drug Discov Today 2001; 6:1153-1164.
3. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55:2325-2333.
4. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997; 272:17118-17125.
5. Su D-S, Meng D, Bertinato P, Bertinato P, Danishefsky SJ, Zheng Y-H, et al. Total synthesis of (-)epothilone B: an extension of the Suzuki coupling method and insights into structure-activity relationships of the epothilones. Angew Chem Int Ed Engl 1997; 36:757-59.
6. Wartmann M, Altmann KH. The biology and medicinal chemistry of epothilones. Curr Med Chem Anticancer Agents 2002; 2:123-148.
7. Nicolaou KC, Sasmal PK, Rassias G, Reddy MV, Altmann KH, Wartmann M, et al. Design, synthesis, and biological properties of highly potent epothilone B analogues. Angew Chem Int Ed Engl 2003; 42:3515-3520.
8. Nicolaou KC, Namoto K, Ritzen A, Ulven T, Shoji M, Li J, D'Amico G, et al. Chemical synthesis and biological evaluation of cis- and trans-12,13-cyclopropyl and 12,13-cyclobutyl epothilones and related pyridine side chain analogues. J Am Chem Soc 2001; 123:9313-9323.
9. Tang L, Qiu RG, Li Y, Katz L. Generation of novel epothilone analogs with cytotoxic activity by biotransformation. J Antibiot (Tokyo) 2003; 56:16-23.
10. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001; 7:1429-1437.
11. Newman RA, Yang J, Raymond M, Finlay V, Cabral F, Vourloumis D, et al. Antitumor efficacy of 26-fluoroepothilone B against human prostate cancer xenografts. Cancer Chemother Pharmacol 2001; 48:319-326.
12. Altmann KH, Bold G, Caravatti G, Florsheimer A, Guagnano V, Wartmann M. Synthesis and biological evaluation of highly potent analogues of epothilones B and D. Bioorg Med Chem Lett 2000; 10:2765-2768.
13. Rothermel J, Wartmann M, Chen T, Hohneker J. EPO906 (epothilone B): a promising novel microtubule stabilizer. Semin Oncol 2003; 30(3 suppl 6):51-55.
14. Spriggs DR, Dupont J, Pezzulli S, Larkin J, Johnson RG, Hannah AL, et al. KOS-862 (Epothilone D): phase 1 dose escalating and pharmacokinetic (P K) study in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003; abstr 894.
15. Piro LD, Rosen LS, Parson M, Cropp GF, McDaid H, Han J, et al. KOS-862 (epothilone D): a comparison of two schedules in patients with advanced malignancies. Proc Am Soc Clin Oncol 2003; abstr 539.
16. Rosen PJ, Rosen LS, Britten C, Parson M, Cropp GF, McDaid H, et al. KOS-862 (epothilone D): results of a phase I dose-escalating trial in patients with advanced malignancies. Proc Am Soc Clin Oncol 2002; abstr 413.
17. Zhou Y, Liu F, Feng L, Uphoff J, Ma W, Hannah AL, et al. KOS-862 (Epothilone D) with 5-fluorouracil in human colon cancer cell lines: synergistic antitumor effects. Proc Am Ass Cancer Res 2003; abstr 2746.
18. Johnson Jr RG, Carney J, Zhong Z, Cropp G, Sherrill M. Oral bioavailability of KOS-862 (Epothilone D), a potent stabilizer of microtubulin polymerization in rats and beagle dogs. Proc Am Ass Cancer Res 2003; abstr 5339.
19. Lin N, Brakora K, Seiden M. BMS-247550 Bristol-Myers Squibb/GBF. Curr Opin Invest Drugs 2003; 4:746-756.
20. Colevas D, Blaytock B, Gravell A. Clinical trials referral resource. Flavopiridol. Oncology (Huntingt) 2002; 16:1204-1205, 1210-1212, 1214.
21. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res 2002; 8:2035-2043.
22. Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM, et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol 2003; 21:1866-1873.
23. Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D, et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res 2004; 10:1289-1298.
24. Agrawal M, Edgerly M, Fojo T, Kotz H. Treatment of recurrent cervical adenocarcinoma with BMS-247550, an epothilone B analog. Gynecol Oncol 2003; 90:96-99.
25. Mekhail T, Chung C, Holden S, Bukowski RM, Eckhardt SG, Cunningham M, et al. Phase I trial of novel epothilone B analog BMS-310705 IV q 21 days. Proc Am Soc Clin Oncol 2003; abstr 515.
26. Sessa C, Perotti A, Malossi A, Capri G, Cresta S, De Braud F, et al. Phase I and pharmacokinetic (PK) study of the novel epothilone BMS-310705 in patients with advanced solid cancer. Proc Am Soc Clin Oncol 2003; abstr 519.
27. Longley RE, Caddigan D, Harmody D, Gunasekera M, Gunasekera SP. Discodermolide - a new, marine-derived immunosuppressive compound. I. In vitro studies. Transplantation 1991; 52:650-656.
28. Harried SS, Lee CP, Yang G, Lee TI, Myles DC. Total synthesis of the potent microtubule-stabilizing agent (+)-discodermolide. J Org Chem 2003; 68:6646-6660.
29. Minguez JM, Kim SY, Giuliano KA, Balachandran R, Madiraju C, Day BW, et al. DP. Synthesis and biological assessment of simplified analogues of the potent microtubule stabilizer (+)-discodermolide. Bioorg Med Chem 2003; 11:3335-3357.
30. Francavilla C, Chen W, Kinder Jr FR. Formal synthesis of (+)-discodermolide. Org Lett 2003; 5:1233-1236.
31. Balachandran R, ter Haar E, Welsh MJ, Grant SG, Day BW. The potent microtubule-stabilizing agent (+)-discodermolide induces apoptosis in human breast carcinoma cells - preliminary comparisons to paclitaxel. Anticancer Drugs 1998; 9:67-76.
32. Kowalski RJ, Giannakakou P, Gunasekera SP, Longley RE, Day BW, Hamel E. The microtubule-stabilizing agent discodermolide competitively inhibits the binding of paclitaxel (Taxol) to tubulin polymers, enhances tubulin nucleation reactions more potently than paclitaxel, and inhibits the growth of paclitaxel-resistant cells. Mol Pharmacol 1997; 52:613-622.
33. Minguez JM, Giuliano KA, Balachandran R, Madiraju C, Curran DP, Day BW. Synthesis and high content cell-based profiling of simplified analogues of the microtubule stabilizer (+)-discodermolide. Mol Cancer Ther 2002; 1:1305-1313.
34. Broker LE, Huisman C, Ferreira CG, Rodriguez JA, Kruyt FA, Giaccone G. Late activation of apoptotic pathways plays a negligible role in mediating the cytotoxic effects of discodermolide and epothilone B in non-small cell lung cancer cells. Cancer Res 2002; 62:4081-4088.
35. ter Haar E, Kowalski RJ, Hamel E, Lin CM, Longley RE, Gunasekera SP, et al. Discodermolide, a cytotoxic marine agent that stabilizes microtubules more potently than taxol. Biochemistry 1996; 35:243-250.
36. He L, Yang CP, Horwitz SB. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 2001; 1:3-10.
37. Martello LA, LaMarche MJ, He L, Beauchamp TJ, Smith AB, Horwitz SB. The relationship between Taxol and (+)-discodermolide: synthetic analogs and modeling studies. Chem Biol 2001; 8:843-855.
38. Martello LA, McDaid HM, Regl DL, Yang CP, Meng D, Pettus TR, et al. Taxol and discodermolide represent a synergistic drug combination in human carcinoma cell lines. Clin Cancer Res 2000; 6:1978-1987.
39. Mita C, Hammond LA, Lockhart AC, Shah M, Curtright J, Chen T, et al. A phase I and pharmacokinetic study of XAA296A (discodermolide) administered once every three weeks in adult patients with advanced solid malignancies. Proc AACR-NCI-EORTC Int Conf 2003; abstr A252.